RxDoctor Payments DataLook up a doctor →

Jessica Lawrence

Nurse Practitioner · Memphis, TNNPI 1609100536

Payments from drug & device makers

$13,341in general payments, 2019–2025

Across 595 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$1K
  • Astellas Pharma US Inc$932
  • Antares Pharma, Inc.$614
  • Coloplast$590
  • plus $6K from 39 others

What the payments were for

  • Travel & lodging$4213%
  • Food & beverage$12,30992%
  • Education$6125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,341 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$263,839
Medicare patients
412
Services billed
85,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide49$667,076
MyrbetriqMirabegron86$68,488
XgevaDenosumab18$55,626
GemtesaVibegron55$50,268
XyostedTestosterone Enanthate13$12,891
Tamsulosin Hcl584$8,648
Testosterone Cypionate96$5,342
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst173$3,249
Solifenacin Succinate44$2,061
Estradiol27$2,061
Trimethoprim20$1,613
Finasteride107$1,313
Dutasteride35$1,144
Oxybutynin Chloride ErOxybutynin Chloride44$999
ValacyclovirValacyclovir Hcl16$683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$932$735,565135 claims
AmgenXgeva$255$55,62618 claims
Sumitomo Pharma America, Inc.Gemtesa$1,332$50,26855 claims
Antares Pharma, Inc.Xyosted$614$12,89113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →